Phase I trial of BHV 0223, a reformulated glutamate modulating agent, as a potential therapy for treatment-resistant mood and general anxiety disorders
Phase of Trial: Phase I
Latest Information Update: 05 Jul 2016
At a glance
- Drugs Riluzole (Primary)
- Indications Generalised anxiety disorder; Mood disorders
- Focus First in man; Pharmacokinetics
- 05 Jul 2016 According to Biohaven Pharmaceuticals media release, as of August 2015, the FDA cleared the Company's IND for BHV-0223.
- 24 Feb 2016 Results published in a Portage Biotech media release.
- 24 Feb 2016 Results were published in a Biohaven Pharmaceutical media release.